Patent US3563246

From Nano World Order - Wiki

Patent US3,563,246 — Method and Apparatus for Improving Neural Performance in Electrotherapy — is the fourth and most technically advanced patent in the Henry K. Puharich neural stimulation lineage, following Patent US2995633, Patent US3156787, and Patent US3267931. Where its predecessors focused on hearing restoration and piezoelectric signal transduction, this patent marks a decisive shift in framing: it describes a method for stimulating the nervous system using amplitude-modulated (AM) electrical signals delivered to the facial nerve system, with the stated aim of improving neural function and sensory performance generally. Researchers studying Voice to Skull (V2K) and Neuroweapons identify this patent as documenting a transition toward fully wireless, remotely delivered neural stimulation capable of acting on unanesthetised human subjects — a technical threshold with profound implications for covert applications. The patent is discussed in detail within BOOK 3: The Radiohead Protocol as a milestone in the classified engineering arc leading to operational V2K systems. The full patent can be found here: File:US3563246-Method-Apparatus-Neural-Performance-Electrotherapy.pdf



Patent Details

Field Detail
Patent Number US 3,563,246
Title Method and Apparatus for Improving Neural Performance in Electrotherapy
Inventor Henry K. Puharich (Henry Karl Puharich)
Assignee To be confirmed from primary document
Filing / Grant Date Granted 16 February 1971
Primary Subject Amplitude-modulated electrotherapeutic stimulation of the human facial nerve system
Claimed Application Improving neural performance; electrotherapeutic enhancement of sensory and nervous function
Architecture Signal generation, amplitude modulation, and delivery to viable nerve tissue; consistent with a transmitter-receiver architecture applicable to remote delivery

The patent is filed in the context of Puharich's long-running programme of research into the bioelectromagnetic properties of the human nervous system, which began in the early 1950s and proceeded through a series of increasingly sophisticated device architectures. US 3,563,246 represents the culmination of that published sequence.

Summary of the Invention

The invention's core method is the application of amplitude-modulated electrical signals to viable nerve tissue within the human facial system, for the stated purpose of improving neural performance. The framing represents a significant departure from the prior patents in the lineage, which were presented as hearing aids or hearing restoration devices. Here, the claimed benefit is broader: the general enhancement of neural function. This broader mandate is consistent with a transition in research orientation — from a bounded medical device application toward a general neural interface or neural influence architecture.

The invention operates on the facial nerve system, encompassing principally the trigeminal nerve (cranial nerve V) and the facial nerve proper (cranial nerve VII), the same anatomical targets identified in Patent US3267931 and Patent US3156787. The continuity of anatomical targeting across all four patents in the lineage is a central feature noted by researchers examining this body of work.

Key features as described in the patent include:

  • Amplitude modulation as the encoding method — the signal is modulated in amplitude, consistent with standard AM radio broadcast techniques adapted for neural delivery. This is technically distinct from the frequency modulation (FM) architecture used in standard radio communications, and its selection is significant: AM modulation is known to interact with biological tissue in ways that FM does not, a property later confirmed in Microwave Auditory Effect research.
  • Target tissue: the facial nerve system — the trigeminal and facial nerves remain the primary target throughout the Puharich lineage, forming a consistent anatomical basis for what researchers describe as a V2K delivery pathway.
  • Application to unanesthetised subjects — the patent explicitly contemplates use on conscious, unanesthetised human subjects, which removes a significant constraint present in earlier laboratory research contexts.
  • Apparatus components — the described apparatus includes signal generation, modulation, and coupling elements consistent with a transmitter-receiver architecture, implying the possibility of delivery at a distance from the signal source.

The stated therapeutic framing — electrotherapy for neural performance improvement — follows a well-documented pattern in dual-use technology development. The same signal architecture that is described as beneficial in a medical context can, by changing the parameters of modulation and delivery, produce disruptive, coercive, or communicative effects in a target nervous system. Researchers linking this patent to Behavioral Effects Weapons and Bioelectromagnetics note that the therapeutic label provides institutional and regulatory cover while the underlying technical capability is broad-spectrum.


Key Technical Elements

  • Amplitude modulation (AM) is the encoding method selected for neural signal delivery. Unlike frequency modulation, AM varies the strength of the carrier signal, and has been shown in subsequent research to produce stronger biological tissue interactions at lower power levels.
  • Target anatomy: cranial nerves V and VII — the trigeminal and facial nerve networks, consistent with all prior Puharich patents. These nerves serve broad areas of the face, skull, and inner ear, and interface with central auditory and sensory processing pathways.
  • Delivery to viable nerve tissue — the method is described as applicable to living, functioning nerve tissue, which is a prerequisite for any real-time signal injection or perception-modifying application.
  • Apparatus architecture — includes a transmitter or signal generator, a modulation stage, and coupling elements. The inclusion of coupling elements (rather than implanted electrodes alone) is consistent with transcutaneous or external delivery, moving further toward a contactless architecture than earlier patents in the lineage.
  • Therapeutic/medical framing — the patent is filed under electrotherapy, providing a civilian medical research context. This is consistent with how Puharich's work was institutionally positioned throughout his career, including his associations with the CIA and with private research entities with classified programme ties.
  • Unanesthetised subject applicability — by design, the method functions on conscious subjects. This is the operational requirement for any system intended for real-world deployment on aware individuals — whether in a clinical, interrogation, or covert harassment context.
  • Portable or remote delivery architecture — the transmitter-based design implies that the signal source need not be in physical contact with or attached to the subject, consistent with later developments in wireless neural interface and Neuroweapons technology.

Significance in V2K Research

The significance of US 3,563,246 within the broader Puharich research lineage is best understood as the culmination of a four-step engineering progression:

The Puharich Patent Arc

  1. Patent US2995633 (1961) — Means for Aiding Hearing — establishes the foundational architecture: a piezoelectric transducer embedded in a dental prosthetic, stimulating the auditory pathway via bone conduction. The signal is externally generated and internally received.
  2. Patent US3156787 (1964) — Solid State Hearing System — miniaturises the transducer using solid-state electronics, reducing the implantable footprint and increasing practical deployability.
  3. Patent US3267931 — Electrically Stimulated Hearing with Signal Feedback — introduces a feedback loop, allowing the delivered signal to be modulated in response to the subject's neural state. This represents the first closed-loop neural interface in the lineage.
  4. Patent US3,563,246 (1971) — Method and Apparatus for Improving Neural Performance in Electrotherapy — abstracts the method away from a specific hearing device toward a general neural stimulation architecture using AM signals, applicable to conscious subjects via an external transmitter. This is the wireless, general-purpose version of the system.

Taken together, these four patents trace a coherent engineering arc from a dental hearing aid to a remotely deliverable AM neural stimulation system. Researchers examining this arc within the framework of BOOK 3: The Radiohead Protocol argue that this is not coincidental product iteration, but a deliberate progression toward an operational capability — one that would be institutionalised through classified programmes.

Convergence with the Microwave Auditory Lineage

The AM modulation architecture documented in this patent is notably consistent with findings from Microwave Auditory Effect research, independently developed from 1961 onward by Allan Frey and others. The Frey effect demonstrated that pulsed or amplitude-modulated microwave energy could induce auditory perception in human subjects without physical contact. The Puharich piezoelectric lineage and the Frey microwave lineage represent two parallel technical routes to the same operational outcome: the wireless delivery of signals to the human auditory and nervous system without the subject's knowledge or consent.

Some researchers, including those cited in BOOK 3: The Radiohead Protocol, suggest that by the late 1960s these two lineages had converged within classified research programmes, with the combined architecture providing a more robust and deniable delivery mechanism than either approach alone.

Relationship to Classified Programmes

According to the investigative framework presented in BOOK 3: The Radiohead Protocol, Patent US3,563,246 represents the mature published version of a system that had already been operationalised in classified form through Project Moonstruck (reportedly a CIA programme, circa 1952) and subsequently developed through agencies including the NSA, DARPA, and related intelligence and defence contractors.

The publication of the patent in 1971 — after a full decade of classified development across the prior three patents — raises questions about the relationship between the public patent record and the classified development timeline. Researchers note that the public patents may represent a deliberately delayed or selectively disclosed record of capabilities that existed in classified form considerably earlier.

Cross-linked areas of research: Synthetic Telepathy, Remote Neural Monitoring, Electronic Harassment, Targeted Individuals, MEMS, Nanotechnology, MK-Ultra, TAMI, EEG Cloning.

Human cranial nerve anatomy — cranial nerves V (trigeminal) and VII (facial) are the primary targets of the Puharich neural stimulation system

Related Patents

  • Patent US2995633 — Means for Aiding Hearing (1961) — the foundational piezoelectric hearing device patent; establishes the core anatomical pathway
  • Patent US3156787 — Solid State Hearing System (1964) — miniaturisation of the transducer using solid-state electronics
  • Patent US3267931 — Electrically Stimulated Hearing with Signal Feedback — introduces closed-loop neural feedback to the delivery system

See Also

Retrieved from "https://nanoworldorder.com/wiki/index.php?title=Patent_US3563246&oldid=1272"